KZA.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 Nov 2023 @ 00:10):

Stats
Today's Volume	454 181
Average Volume	473 092
Market Cap	18.91M
EPS	$0 ( 2024-02-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.727
ATR14	$0.00800 (10.00%)

Volume Correlation

Long: -0.67 (moderate negative)

Short: 0.15 (neutral)

Signal:(43.949) Neutral

Kazia Therapeutics Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kazia Therapeutics Ltd Correlation - Currency/Commodity

-0.74
( moderate negative )

-0.49
( neutral )

0.00
( neutral )

-0.60
( weak negative )

-0.05
( neutral )

Kazia Therapeutics Ltd Financials

Annual	2022
Revenue:	$555.00
Gross Profit:	$555.00 (100.00 %)
EPS:	$-0.110

FY	2022
Revenue:	$555.00
Gross Profit:	$555.00 (100.00 %)
EPS:	$-0.110

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.190

FY	2021
Revenue:	$15.18M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0716

Financial Reports:

No articles found.

Kazia Therapeutics Ltd Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Kazia Therapeutics Ltd

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.